Whalesbook
📉 The Financial Deep Dive
The Numbers:
Rubicon Research posted a strong Q3 FY26 with revenue from operations growing a significant 51.7% year-on-year to ₹4,755 million (vs ₹3,134 million in Q3 FY25). For the nine months ended December 31, 2025 (9M FY26), revenue grew 33.9% YoY to ₹12,400 million. Profit After Tax (PAT) surged 91.2% YoY in Q3 FY26 to ₹728 million (vs ₹381 million in Q3 FY25). For 9M FY26, PAT increased 73.2% YoY to ₹1,700 million. Earnings Per Share (EPS) grew 79.1% YoY to ₹4.41 in Q3 FY26.
The Quality:
Despite robust top-line and bottom-line growth, Gross Margin percentage saw a sequential and year-on-year decline. This was attributed to increased reliance on outsourced manufacturing due to internal capacity constraints. However, the company's Operating EBITDA margin was maintained within the expected range of 22-23%, standing at 22.7% in Q3 FY26, demonstrating effective cost control. Post-IPO capital infusion has significantly boosted Shareholders' Funds to ₹11,938 million as of December 31, 2025. Fixed Assets have increased substantially to ₹5,500 million, indicative of capital expenditure. Cash and cash equivalents stand at ₹3,338 million. Borrowings have reduced to ₹2,853 million. Cash flow from operations for 9M FY26 was ₹1,395 million. Investing activities used ₹3,400 million, including the Pithampur acquisition and CapEx. Financing activities generated ₹3,268 million in 9M FY26, primarily from IPO proceeds.
The Grill:
Management anticipates continued strong revenue visibility. Key focus areas include the ramp-up of the Pithampur facility (operational mid-CY26, commercialization from Q1CY27), which is expected to reduce reliance on outsourced manufacturing and consequently improve Gross Margins. R&D remains a strategic priority, with plans to maintain expenses at 10-11% of revenue, supporting future growth drivers. The incremental revenue multiple on lagging R&D spend stands at 5.7x annualized FY26.
🚩 Risks & Outlook
Specific Risks:
The primary short-to-medium term risk is the temporary compression of Gross Margins due to outsourced manufacturing. Investors will monitor the Pithampur facility's timeline and ramp-up efficiency closely. Execution risks associated with integrating acquisitions and scaling operations also remain.
The Forward View:
Rubicon Research is well-positioned for continued growth, leveraging its USD-denominated revenue base. The successful commissioning and commercialization of the Pithampur facility will be crucial for margin recovery and long-term profitability. Continued investment in R&D is expected to yield future product pipeline and growth opportunities. Investors should watch for updates on capacity utilization, margin trends, and new product developments in the upcoming quarters.